Analyst Price Target is $9.75
▲ +66.04% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sientra in the last 3 months. The average price target is $9.75, with a high forecast of $11.00 and a low forecast of $8.24. The average price target represents a 66.04% upside from the last price of $5.87.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Sientra. This Buy consensus rating has held steady for over two years.
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini on August 29, 2003 and is headquartered in Santa Barbara, CA.